Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2017

01-08-2017 | Original Article

Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection

Authors: Ryuma Tokunaga, Yasuo Sakamoto, Shigeki Nakagawa, Daisuke Izumi, Keisuke Kosumi, Katsunobu Taki, Takaaki Higashi, Tatsunori Miyata, Yuji Miyamoto, Naoya Yoshida, Hideo Baba

Published in: International Journal of Clinical Oncology | Issue 4/2017

Login to get access

Abstract

Background

Various systemic inflammatory and nutritional scores have been reported to predict postoperative outcomes. This study aimed to investigate the best systemic inflammatory and nutritional scores in colorectal cancer (CRC) patients who underwent potentially curative resection.

Method

We evaluated 468 consecutive CRC patients in this study. Comparisons of systemic inflammatory and nutritional scores, including the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), prognostic index (PI), prognostic nutritional index (PNI), and modified Glasgow prognostic score (mGPS), were performed using univariate/multivariate analyses for patient survival.

Results

The PNI and mGPS, but not the NLR, PLR, and PI, were significantly associated with overall and relapse-free survival. The mGPS, but not the PNI, was strongly correlated with TNM stage (P < 0.001). Cox multivariate analysis showed that both the PNI and mGPS were exclusive independent prognostic factors for both overall and relapse-free survival (P < 0.001). Furthermore, the PNI status predicted patient survival more clearly than the mGPS in combination with TNM stage.

Conclusions

This study suggests that the PNI and mGPS are useful predictive scores in CRC patients who undergo potentially curative resection, especially the PNI in combination with TNM stage. Routine evaluation of the host status using the scores may be useful in CRC treatment.
Appendix
Available only for authorised users
Literature
1.
Oshima H, Nakayama M, Han TS et al (2015) Suppressing TGFbeta signaling in regenerating epithelia in an inflammatory microenvironment is sufficient to cause invasive intestinal cancer. Cancer Res 75:766–776CrossRefPubMed
2.
Bozzetti F (2002) Rationale and indications for preoperative feeding of malnourished surgical cancer patients. Nutrition 18:953–959CrossRefPubMed
3.
Meguid MM, Mughal MM, Debonis D et al (1986) Influence of nutritional status on the resumption of adequate food intake in patients recovering from colorectal cancer operations. Surg Clin North Am 66:1167–1176CrossRefPubMed
4.
Onodera T, Goseki N, Kosaki G (2014) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 10:1–7
5.
Onodera T, Goseki N, Kosaki G (1984) Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi 85:1001–1005PubMed
6.
Gomes de Lima KV, Maio R (2012) Nutritional status, systemic inflammation and prognosis of patients with gastrointestinal cancer. Nutr Hosp 27:707–714PubMed
7.
Park JH, Watt DG, Roxburgh CS et al. (2015) colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host. Ann Surg. 236(2): 326−36
8.
The Japanese society for cancer of the colon and rectum (2005) JSCCR guidelines 2005 for the treatment of colorectal cancer. Kanehara and Co., Ltd, Tokyo
9.
The Japanese society for cancer of the colon and rectum (2010) JSCCR Guidelines 2010 for the treatment of colorectal cancer. Kanehara and Co., Ltd, Tokyo
10.
Watanabe T, Itabashi M, Shimada Y et al (2012) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 17:1–29CrossRefPubMed
11.
Sobin LHGMWC (2009) TNM classification of malignant tumours, 7th edn. Wiley-Blackwell, New York
12.
Mallappa S, Sinha A, Gupta S et al (2013) Preoperative neutrophil to lymphocyte ratio >5 is a prognostic factor for recurrent colorectal cancer. Colorectal Dis 15:323–328CrossRefPubMed
13.
Smith RA, Bosonnet L, Raraty M et al (2009) Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg 197:466–472CrossRefPubMed
14.
Proctor MJ, Morrison DS, Talwar D et al (2011) A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur J Cancer 47:2633–2641CrossRefPubMed
15.
Mohri Y, Inoue Y, Tanaka K et al (2013) Prognostic nutritional index predicts postoperative outcome in colorectal cancer. World J Surg 37:2688–2692CrossRefPubMed
16.
Tarantino I, Warschkow R, Worni M et al (2012) Elevated preoperative CEA is associated with worse survival in stage I-III rectal cancer patients. Br J Cancer 107:266–274CrossRefPubMedPubMedCentral
17.
Stiksma J, Grootendorst DC, van der Linden PW (2014) CA 19-9 as a marker in addition to CEA to monitor colorectal cancer. Clin Colorectal Cancer 13:239–244CrossRefPubMed
18.
19.
Heys SD, Walker LG, Deehan DJ et al (1998) Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb 43:163–168PubMed
20.
Kinoshita A, Onoda H, Imai N et al (2012) Comparison of the prognostic value of inflammation-based prognostic scores in patients with hepatocellular carcinoma. Br J Cancer 107:988–993CrossRefPubMedPubMedCentral
21.
Guthrie GJ, Roxburgh CS, Farhan-Alanie OM et al (2013) Comparison of the prognostic value of longitudinal measurements of systemic inflammation in patients undergoing curative resection of colorectal cancer. Br J Cancer 109:24–28CrossRefPubMedPubMedCentral
22.
Cedres S, Torrejon D, Martinez A et al (2012) Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer. Clin Transl Oncol 14:864–869CrossRefPubMed
23.
Jin H, Zhang G, Liu X et al (2013) Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. World J Surg Oncol 11:112CrossRefPubMedPubMedCentral
24.
Lee S, Oh SY, Kim SH et al (2013) Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 13:350CrossRefPubMedPubMedCentral
25.
Yao Y, Yuan D, Liu H et al (2013) Pretreatment neutrophil to lymphocyte ratio is associated with response to therapy and prognosis of advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy. Cancer Immunol Immunother 62:471–479CrossRefPubMed
26.
Tokunaga R, Sakamoto Y, Nakagawa S et al (2015) Prognostic nutritional index predicts severe complications, recurrence, and poor prognosis in patients with colorectal cancer undergoing primary tumor resection. Dis Colon Rectum 58:1048–1057CrossRefPubMed
27.
Dutta S, Crumley AB, Fullarton GM et al (2012) Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. Am J Surg 204:294–299CrossRefPubMed
28.
Miyamoto Y, Baba Y, Sakamoto Y et al (2015) Sarcopenia is a negative prognostic factor after curative resection of colorectal cancer. Ann Surg Oncol 22:2663–2668CrossRefPubMed
29.
Moon HG, Ju YT, Jeong CY et al (2008) Visceral obesity may affect oncologic outcome in patients with colorectal cancer. Ann Surg Oncol 15:1918–1922CrossRefPubMed
Metadata
Title
Comparison of systemic inflammatory and nutritional scores in colorectal cancer patients who underwent potentially curative resection
Authors
Ryuma Tokunaga
Yasuo Sakamoto
Shigeki Nakagawa
Daisuke Izumi
Keisuke Kosumi
Katsunobu Taki
Takaaki Higashi
Tatsunori Miyata
Yuji Miyamoto
Naoya Yoshida
Hideo Baba
Publication date
01-08-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1102-5

Other articles of this Issue 4/2017

International Journal of Clinical Oncology 4/2017 Go to the issue

Invited Review Article

Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance

Original Article

A mathematical theory of shape and neuro-fuzzy methodology-based diagnostic analysis: a comparative study on early detection and treatment planning of brain cancer

Letter to the Editor

Higher prevalence of the TNF-α G-308A heterozygous genotype in a South Indian population

Original Article

A phase I/II study on stereotactic body radiotherapy with real-time tumor tracking using CyberKnife based on the Monte Carlo algorithm for lung tumors

Original Article

Do all patients in the phase I oncology trials need to be hospitalized? Domestic but outstanding issues for globalization of drug development in Japan

Original Article

Patient perceptions of symptoms and concerns during cancer chemotherapy: ‘affects my family’ is the most important
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits